This article is more than 5 years old. Information may no longer be current.

Santen to acquire InnFocus

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Santen Pharmaceutical announced it has entered into a definitive agreement to acquire InnFocus, developer of the MicroShunt glaucoma implant device.

Santen will acquire InnFocus for an upfront payment of $225 million, plus performance-based considerations upon achievement of development, commercial and regulatory milestones, according to a press release.

The MicroShunt, which has a CE mark in Europe, is designed to lower and sustain IOP for the treatment of primary open-angle glaucoma. In clinical trials outside of the U.S., the device “has shown significant and sustainable lowering of IOP” alone or in combination with cataract surgery, according to the release.

“With this acquisition, Santen will strengthen our glaucoma pipeline and stay at the forefront of innovation in ophthalmology. This agreement is in line with our long-term vision to become a specialized pharmaceutical company with a global presence,” Akira Kurokawa, president and CEO of Santen, said in the release.

The MicroShunt is currently in late-stage clinical studies in the U.S. and Europe in advance of a premarket approval application to the FDA, according to the release.